Stay updated with breaking news from Nasdaq Dnli. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $14.56 and last traded at $14.79, with a volume of 172121 shares changing hands. The stock had previously closed at $15.56. Analyst Ratings Changes DNLI has been the […]
Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) Director Vicki L. Sato sold 1,666 shares of the company’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $18.29, for a total transaction of $30,471.14. Following the completion of the sale, the director now directly owns 118,043 shares […]
Denali Therapeutics (NASDAQ:DNLI – Get Free Report) had its price objective dropped by analysts at UBS Group from $70.00 to $32.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. UBS Group’s price objective suggests a potential upside of 65.29% from […]
Profund Advisors LLC lowered its stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 13.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 40,154 shares of the company’s stock after selling 6,321 shares during the quarter. Profund Advisors LLC’s holdings in Denali Therapeutics […]
Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) Director Steve E. Krognes sold 2,750 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $17.29, for a total value of $47,547.50. Following the completion of the transaction, the director now directly owns 139,841 shares […]